Testing new biomarker tests on pleural biopsies in pleural mesothelioma
Tests a new method to judge stage and outlook in pleural mesothelioma.
Plain-language title generated from the registry record
Registry title: Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Brigham and Women's HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dana-Farber Cancer Institute
- Trial code
- NCT03683680
- Record updated
- 5 May 2026
- Original description
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.Read full original descriptionShow less
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
Inclusion: All adult patients with a diagnosis of malignant pleural mesothelioma undergoing; diagnostic pleural biopsy; pleuroscopy; and/or VATS resections; Participants must be 18 years of age or older.
Exclusion: surgery,; -Any patient who is found to be unsuitable for; treatment; diagnosis,.